Marshall Wace
DNLI icon

Marshall Wace’s Denali Therapeutics DNLI Stock Holding History

Marshall Wace’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Sell
549,830
-441,438
-45% -$9.07M 0.01% 884
2026
Q1 		$19M Buy
991,268
+227,376
+30% +$4.52M 0.02% 720
2025
Q4 		$12.6M Sell
763,892
-23,137
-3% -$391K 0.01% 788
2025
Q3 		$11.4M Sell
787,029
-618,221
-44% -$8.88M 0.01% 872
2025
Q2 		$19.7M Sell
1,405,250
-783,172
-36% -$11M 0.02% 591
2025
Q1 		$29.8M Buy
2,188,422
+399,685
+22% +$7.66M 0.04% 405
2024
Q4 		$36.5M Sell
1,788,737
-178,404
-9% -$4.57M 0.04% 359
2024
Q3 		$57.3M Sell
1,967,141
-451,692
-19% -$11.2M 0.07% 244
2024
Q2 		$56.2M Buy
2,418,833
+272,454
+13% +$5.23M 0.08% 242
2024
Q1 		$44M Buy
2,146,379
+478,982
+29% +$9M 0.07% 285
2023
Q4 		$35.8M Buy
+1,667,397
New +$33M 0.06% 315
2023
Q2 		– Sell
-350,539
Closed -$8.08M – 2560
2023
Q1 		$8.08M Sell
350,539
-610,100
-64% -$16.8M 0.02% 787
2022
Q4 		$26.7M Buy
960,639
+284,769
+42% +$8.47M 0.06% 361
2022
Q3 		$20.7M Sell
675,870
-141,780
-17% -$4.61M 0.05% 448
2022
Q2 		$24.1M Buy
817,650
+664,795
+435% +$17.4M 0.05% 390
2022
Q1 		$4.92M Sell
152,855
-231,089
-60% -$7.95M 0.01% 1376
2021
Q4 		$17.1M Sell
383,944
-147,414
-28% -$6.98M 0.03% 555
2021
Q3 		$26.8M Sell
531,358
-114,641
-18% -$6.46M 0.11% 193
2021
Q2 		$50.7M Buy
645,999
+546,481
+549% +$33.8M 0.23% 75
2021
Q1 		$5.68M Buy
+99,518
New +$6.66M 0.03% 762
2020
Q4 		– Sell
-325,168
Closed -$11.7M – 1934
2020
Q3 		$11.7M Buy
325,168
+286,598
+743% +$8.63M 0.07% 259
2020
Q2 		$933K Sell
38,570
-203,550
-84% -$4.79M 0.01% 1016
2020
Q1 		$4.24M Buy
242,120
+195,743
+422% +$4.08M 0.04% 426
2019
Q4 		$808K Buy
+46,377
New +$772K 0.01% 1035
2019
Q2 		– Sell
-15,473
Closed -$359K – 1449
2019
Q1 		$359K Buy
+15,473
New +$324K ﹤0.01% 1226

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's DNLI Position: Q2 2026 in Review

Marshall Wace reduced its Denali Therapeutics (DNLI) stake by 45% in Q2 2026, selling an estimated $9.07M and leaving 549,830 shares worth $14.1M. The position accounts for 0.01% of the portfolio, ranked #884.

Marshall Wace first reported a position in DNLI in Q1 2019 and has held it in 25 quarters since. The position peaked at $57.3M in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Marshall Wace held 549,830 shares of Denali Therapeutics worth $14.1M as of Q2 2026.
  • Marshall Wace sold 441,438 Denali Therapeutics shares in Q2 2026, an estimated $9.07M.
  • Denali Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #884 holding.
  • Marshall Wace first reported a position in Denali Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • Marshall Wace's Denali Therapeutics position peaked at $57.3M in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.